Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden
Rahel Schwotzer(University Hospital of Zurich), B. Gerber(University of Zurich), Georg Stüssi(Institute of Oncology Research), Erika Lerch(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sofie Brouwers, Christine Waibel(Kantonsspital Baden), Guido Ghilardi(Hospital of the University of Pennsylvania), Harald Seeger(University Hospital of Zurich), Thomas Fehr(University Hospital of Zurich), Stefanie Pederiva(Kantonsspital Baden), Andreas J. Flammer(Zurich Heart House), Elena Bianchi(Institute of Oncology Research), Raphael Heimgartner(Kantonsspital Graubünden), Clemens B. Caspar(Kantonsspital Baden), Markus G. Manz(Ospedale San Giovanni Bellinzona)
Cited by 34
Related Papers
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
|European Heart Journal|2024|1.9k
The Assessment of Endothelial Function
|Circulation|2012|1.1k
Organ Dysfunction, Injury and Failure in Acute Heart Failure: From Pathophysiology to Diagnosis and Management. A Review on Behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2017|406
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308